Evicenter
Xarelto (rivaroxaban), All indications
Manufacturer
Janssen Pharmaceuticals, Inc.
Prescribing information
Xarelto (opens in a new tab)
Questions
37
Last updated

All questions

Safety: Xarelto (rivaroxaban), all indications

10 questions · 3 sources

Monitoring

Does Xarelto need INR or coagulation monitoring?

Note: The first passage is from the Prescribing Information and the second is the manufacturer's FAQ answer. For atrial fibrillation, the Prescribing Information separately advises periodic assessment of renal function (see the kidney dosing question).

Warnings

What is the Xarelto boxed warning about stopping early and spinal hematoma?

“WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA A. Premature discontinuation of XARELTO increases the risk of thrombotic events Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. If anticoagulation with XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.3, 2.4), Warnings and Precautions (5.1), and Clinical Studies (14.1)]. B. Spinal/epidural hematoma Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non- steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between the administration of XARELTO and neuraxial procedures is not known [see Warnings and Precautions (5.2, 5.3) and Adverse Reactions (6.2)]. Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see Warnings and Precautions (5.3)].” (opens the source at this quote in a new tab)

Does Xarelto increase the risk of bleeding?

Who should not take Xarelto (contraindications)?

Can patients taking Xarelto have spinal or epidural anesthesia?

Can Xarelto be used with a prosthetic heart valve or after TAVR?

Is Xarelto recommended in antiphospholipid syndrome?

Bleeding management

Is there a reversal agent for Xarelto?

Note: The Prescribing Information revised 03/2026 and the treatment considerations page state that a specific reversal agent is not available. The FAQ page of the Xarelto HCP site, as captured on November 13, 2026, states in its expanded answer to the reversal question that "An agent to reverse the anti-factor Xa activity of rivaroxaban is available", while the Important Safety Information on the same page states that one is not available; the Prescribing Information is quoted here.

Side effects

What other side effects have been reported with Xarelto after approval?

Safety

What should be done after a Xarelto overdose?